Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Indacaterol 27.5 mcg; Drug: Indacaterol 37.5; Drug: Indacaterol 55 mcg; Drug: Indacaterol 75 mcg; Drug: Indacaterol 150 mcg; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified October 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Rhinoconjunctivitis
Interventions: Biological: ToleroMune HDM; Biological: Placebo
Sponsors: Circassia Limited; Circassia Limited; Adiga Life Sciences
Not yet recruiting – verified September 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American …
MarketWatch (press release) 5, during the American College of Allergy, Asthma and Immunology annual meeting in Boston. "In addition to a reduced rate of serious bacterial infections, the phase III study data suggest potentially useful attributes of HyQ, such as the possibility … |
View full post on asthma – Google News
Condition: Asthma Patients
Interventions: Drug: AZD1981; Drug: AZD1981; Drug: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
|
Safety and Tolerability of Regadenoson in Patients With Asthma or COPD
PR Newswire (press release) This multicenter study included 532 patients with asthma and 467 patients with chronic obstructive pulmonary disease (COPD) who were randomized to receive a … |
View full post on asthma – Google News